Danish pharma giant Novo Nordisk entered a deal to acquire small biotech Ziylo, gaining access to its next-generation glucose-sensitive insulins for diabetes. The deal signed on 17 August could be worth more than $800 million for the Bristol, UK-based startup if all milestones are met. Read more in Nature Biotechnology.